{"id":"https://openalex.org/W3171007561","doi":"https://doi.org/10.1200/jco.2021.39.15_suppl.8035","title":"Daratumumab (DARA) maintenance therapy following DARA + cyclophosphamide, bortezomib, and dexamethasone (CyBorD) induction therapy in multiple myeloma (MM): End-of-study analysis of LYRA.","display_name":"Daratumumab (DARA) maintenance therapy following DARA + cyclophosphamide, bortezomib, and dexamethasone (CyBorD) induction therapy in multiple myeloma (MM): End-of-study analysis of LYRA.","publication_year":2021,"publication_date":"2021-05-20","ids":{"openalex":"https://openalex.org/W3171007561","doi":"https://doi.org/10.1200/jco.2021.39.15_suppl.8035","mag":"3171007561"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2021.39.15_suppl.8035","doi":"https://doi.org/10.1200/jco.2021.39.15_suppl.8035","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2021.39.15_suppl.8035","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5043351209","display_name":"Robert M. Rifkin","orcid":"https://orcid.org/0000-0003-3141-1518","observed_orcids":["https://orcid.org/0000-0003-3141-1518"]},"institutions":[{"id":"https://openalex.org/I4210140702","display_name":"Rocky Mountain Cancer Centers","ror":"https://ror.org/03ynhs115","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210140702"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert M. Rifkin","raw_affiliation_strings":["US Oncology Research, Rocky Mountain Cancer Centers, Denver, CO;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"US Oncology Research, Rocky Mountain Cancer Centers, Denver, CO;","institution_ids":["https://openalex.org/I4210140702"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035594574","display_name":"Jason M. Melear","orcid":"https://orcid.org/0009-0008-7943-8908","observed_orcids":["https://orcid.org/0009-0008-7943-8908"]},"institutions":[{"id":"https://openalex.org/I2800124591","display_name":"Texas Oncology","ror":"https://ror.org/02ketev28","country_code":"US","type":"facility","lineage":["https://openalex.org/I2800124591"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jason M. Melear","raw_affiliation_strings":["Texas Oncology\u2013Austin, Austin, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Texas Oncology\u2013Austin, Austin, TX;","institution_ids":["https://openalex.org/I2800124591"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086470642","display_name":"Edward Anthony Faber","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210153992","display_name":"Oncology Hematology Care","ror":"https://ror.org/04gqr8882","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210153992"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Edward Faber","raw_affiliation_strings":["Oncology Hematology Care, Inc., Cincinnati, OH;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology Hematology Care, Inc., Cincinnati, OH;","institution_ids":["https://openalex.org/I4210153992"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113514827","display_name":"William Bensinger","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"William I. Bensinger","raw_affiliation_strings":["Swedish Cancer Institute, Seattle, WA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Swedish Cancer Institute, Seattle, WA;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061916244","display_name":"John M. Burke","orcid":"https://orcid.org/0000-0002-5144-6710","observed_orcids":["https://orcid.org/0000-0002-5144-6710"]},"institutions":[{"id":"https://openalex.org/I4210140702","display_name":"Rocky Mountain Cancer Centers","ror":"https://ror.org/03ynhs115","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210140702"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John M. Burke","raw_affiliation_strings":["US Oncology Research, Rocky Mountain Cancer Centers, Aurora, CO;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"US Oncology Research, Rocky Mountain Cancer Centers, Aurora, CO;","institution_ids":["https://openalex.org/I4210140702"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018302007","display_name":"Mohit Narang","orcid":"https://orcid.org/0000-0002-8701-6210","observed_orcids":["https://orcid.org/0000-0002-8701-6210"]},"institutions":[{"id":"https://openalex.org/I4210092295","display_name":"Maryland Oncology Hematology","ror":"https://ror.org/00npraj80","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210092295"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mohit Narang","raw_affiliation_strings":["US Oncology Research, Maryland Oncology Hematology, Columbia, MD;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"US Oncology Research, Maryland Oncology Hematology, Columbia, MD;","institution_ids":["https://openalex.org/I4210092295"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030896087","display_name":"Don Ambrose Stevens","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I202709704","display_name":"Norton Healthcare","ror":"https://ror.org/0266h1q26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I202709704"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Don A. Stevens","raw_affiliation_strings":["Norton Health Care, Louisville, KY;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Norton Health Care, Louisville, KY;","institution_ids":["https://openalex.org/I202709704"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111989568","display_name":"Kathleen S Gray","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4391767992","display_name":"Janssen Scientific Affairs (United States)","ror":"https://ror.org/04w4xsz15","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4391767992"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kathleen Gray","raw_affiliation_strings":["Janssen Scientific Affairs, LLC, Horsham, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Scientific Affairs, LLC, Horsham, PA;","institution_ids":["https://openalex.org/I4391767992"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037878488","display_name":"Yana Lutska","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4391767992","display_name":"Janssen Scientific Affairs (United States)","ror":"https://ror.org/04w4xsz15","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4391767992"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yana Lutska","raw_affiliation_strings":["Janssen Scientific Affairs, LLC, Horsham, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Scientific Affairs, LLC, Horsham, PA;","institution_ids":["https://openalex.org/I4391767992"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017651424","display_name":"Padma Bobba","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4391767992","display_name":"Janssen Scientific Affairs (United States)","ror":"https://ror.org/04w4xsz15","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4391767992"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Padma Bobba","raw_affiliation_strings":["Janssen Scientific Affairs, LLC, Horsham, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Scientific Affairs, LLC, Horsham, PA;","institution_ids":["https://openalex.org/I4391767992"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047540200","display_name":"Keqin Qi","orcid":"https://orcid.org/0000-0002-8942-2888","observed_orcids":["https://orcid.org/0000-0002-8942-2888"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Keqin Qi","raw_affiliation_strings":["Janssen Research & Development, LLC, Titusville, NJ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Research & Development, LLC, Titusville, NJ;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101468087","display_name":"Ming Qi","orcid":"https://orcid.org/0000-0002-7014-2640","observed_orcids":["https://orcid.org/0000-0002-7014-2640"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ming Qi","raw_affiliation_strings":["Janssen Research & Development, LLC, Spring House, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Research & Development, LLC, Spring House, PA;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112026819","display_name":"Thomas S. Lin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4391767992","display_name":"Janssen Scientific Affairs (United States)","ror":"https://ror.org/04w4xsz15","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4391767992"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas S. Lin","raw_affiliation_strings":["Janssen Scientific Affairs, LLC, Horsham, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Scientific Affairs, LLC, Horsham, PA;","institution_ids":["https://openalex.org/I4391767992"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5024431512","display_name":"Habte Aragaw Yimer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800124591","display_name":"Texas Oncology","ror":"https://ror.org/02ketev28","country_code":"US","type":"facility","lineage":["https://openalex.org/I2800124591"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Habte Aragaw Yimer","raw_affiliation_strings":["US Oncology Research, Texas Oncology \u2013 Tyler, Tyler, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"US Oncology Research, Texas Oncology \u2013 Tyler, Tyler, TX;","institution_ids":["https://openalex.org/I2800124591"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":6,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"39","issue":"15_suppl","first_page":"8035","last_page":"8035"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/daratumumab","display_name":"daratumumab","score":0.9860000014305115},{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.8899999856948853},{"id":"https://openalex.org/keywords/maintenance-therapy","display_name":"maintenance therapy","score":0.9490000009536743},{"id":"https://openalex.org/keywords/cybord","display_name":"CyBorD","score":0.7590000033378601},{"id":"https://openalex.org/keywords/cyclophosphamide","display_name":"cyclophosphamide","score":0.8159999847412109},{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/dexamethasone","display_name":"dexamethasone","score":0.9990000128746033},{"id":"https://openalex.org/keywords/newly-diagnosed-multiple-myeloma","display_name":"newly diagnosed multiple myeloma","score":0.8429999947547913},{"id":"https://openalex.org/keywords/relapsed-multiple-myeloma","display_name":"relapsed multiple myeloma","score":0.9990000128746033},{"id":"https://openalex.org/keywords/autologous-stem-cell-transplantation","display_name":"autologous stem cell transplantation","score":0.9610000252723694},{"id":"https://openalex.org/keywords/deep-response","display_name":"deep response","score":0.39399999380111694},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8529999852180481},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.5690000057220459},{"id":"https://openalex.org/keywords/lyra","display_name":"Lyra","score":0.5099999904632568}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7780795693397522},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.6223105192184448},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.5906904339790344},{"id":"https://openalex.org/C2781119759","wikidata":"https://www.wikidata.org/wiki/Q5222113","display_name":"Daratumumab","level":4,"score":0.5817621350288391},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5350578427314758},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.5243732929229736},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.5201164484024048},{"id":"https://openalex.org/C2778283404","wikidata":"https://www.wikidata.org/wiki/Q6736822","display_name":"Maintenance therapy","level":3,"score":0.5143309831619263},{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.4981698989868164},{"id":"https://openalex.org/C2780401358","wikidata":"https://www.wikidata.org/wiki/Q422252","display_name":"Dexamethasone","level":2,"score":0.4685424566268921},{"id":"https://openalex.org/C2779050716","wikidata":"https://www.wikidata.org/wiki/Q4826373","display_name":"Autologous stem-cell transplantation","level":3,"score":0.445756196975708},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.41373273730278015},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.32026922702789307},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.19529849290847778}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2021.39.15_suppl.8035","doi":"https://doi.org/10.1200/jco.2021.39.15_suppl.8035","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2021.39.15_suppl.8035","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9789000153541565}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320337415","display_name":"Janssen Research and Development","ror":"https://ror.org/03qd7mz70"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2991190124","https://openalex.org/W4283319829","https://openalex.org/W2899258057","https://openalex.org/W2912868691","https://openalex.org/W2764009246","https://openalex.org/W4417013318","https://openalex.org/W2955678973","https://openalex.org/W2979985142","https://openalex.org/W3167376861","https://openalex.org/W2951350926"],"abstract_inverted_index":{"8035":[0],"Background:":[1],"LYRA":[2],"is":[3],"a":[4,198,249,410],"community":[5],"practice-based,":[6],"phase":[7],"2,":[8],"single-arm":[9],"study":[10,367],"(NCT02951819)":[11],"evaluating":[12],"DARA":[13,32,49,84,114,157,388],"+":[14,33,85],"CyBorD":[15,34,86,393],"as":[16,396],"an":[17,45],"immunomodulatory":[18],"drug-sparing":[19],"regimen":[20],"in":[21,35,231,241,316,326,342,360,372,399,403,416],"MM.":[22],"The":[23],"primary":[24],"analysis":[25,59],"demonstrated":[26],"the":[27,56,317,332,346,376],"safety":[28,427],"and":[29,40,44,73,102,120,133,162,194,202,214,225,229,237,239,259,275,282,294,304,352,394],"efficacy":[30,312],"of":[31,60,77,83,122,188,200,220,223,252,310,328,344,362,374,381,414,419],"newly":[36],"diagnosed":[37],"MM":[38,42,69],"(NDMM)":[39],"relapsed":[41],"(RMM),":[43],"update":[46],"showed":[47],"that":[48],"maintenance":[50,154,395],"therapy":[51,78],"deepened":[52],"responses.":[53],"We":[54],"present":[55],"final":[57],"end-of-study":[58],"LYRA.":[61],"Methods:":[62],"US":[63],"pts":[64,141,184,189,196,233,243,279,382,404],"aged":[65],"\u226518":[66],"years":[67],"with":[68,156,331,392,405,409],"per":[70],"IMWG":[71],"criteria":[72],"\u22641":[74],"prior":[75],"line":[76],"received":[79,150,197],"4-8":[80],"induction":[81,204,391],"cycles":[82,155],"(cyclophosphamide":[87],"300":[88],"mg/m2":[89,95],"PO":[90,107],"weekly":[91],"[QW];":[92],"bortezomib":[93],"1.5":[94],"SC":[96],"on":[97,118],"Days":[98],"[D]":[99],"1,":[100],"8,":[101],"15;":[103],"dexamethasone":[104],"40":[105],"mg":[106],"or":[108,407],"IV":[109,115,160],"QW":[110,127],"every":[111],"28":[112],"days;":[113],"8":[116,203],"mg/kg":[117,126,130,135,159],"D1":[119],"D2":[121],"cycle":[123],"[C]1,":[124],"16":[125,129,134,158],"C1D8-C2,":[128],"Q2W":[131],"C3-6,":[132],"Q4W":[136,161],"C7-8).":[137],"After":[138],"induction,":[139],"eligible":[140],"could":[142],"receive":[143,285],"autologous":[144],"stem":[145],"cell":[146],"transplantation":[147],"(ASCT).":[148],"Pts":[149],"up":[151,166],"to":[152,167,358,366],"12":[153,218,308],"were":[163,185,227,263,273,292,378,429],"followed":[164],"for":[165,266,277,390],"36":[168],"months":[169,219,309],"after":[170],"induction.":[171],"Results:":[172],"In":[173],"total,":[174],"101":[175],"(NDMM,":[176],"n":[177,181],"=":[178,182],"87;":[179],"RMM,":[180,408],"14)":[183],"enrolled;":[186],"36%":[187],"had":[190,383],"high-risk":[191],"cytogenetics.":[192],"NDMM":[193,208,232,242,267,278,406,417],"RMM":[195,298],"median":[199,250,255],"6":[201],"cycles,":[205],"respectively.":[206],"Among":[207,297],"pts,":[209,299,330,345,363],"44.8%":[210],"(39/87)":[211],"underwent":[212,235,302],"ASCT":[213,303,420],"72.4%":[215],"(63/87)":[216],"completed":[217,307],"maintenance.":[221],"Rates":[222],"\u2265VGPR":[224],"\u2265CR":[226],"82.1%":[228],"48.7%":[230],"who":[234,244,280],"ASCT,":[236,286],"70.2%":[238],"29.8%":[240],"did":[245,281,283],"not":[246,264,284],"(Table).":[247,296],"With":[248,422],"follow-up":[251],"35.7":[253],"months,":[254],"progression-free":[256],"survival":[257,261],"(PFS)":[258],"overall":[260],"(OS)":[262],"reached":[265],"pts.":[268],"Estimated":[269],"36-month":[270,289],"PFS":[271,412],"rates":[272,291],"69.3%":[274],"72.6%":[276],"respectively;":[287],"estimated":[288],"OS":[290],"94.9%":[293],"84.3%":[295],"7.1%":[300],"(1/14)":[301],"50.0%":[305],"(7/14)":[306],"maintenance;":[311],"outcomes":[313],"are":[314],"shown":[315],"Table.":[318],"Grade":[319],"3/4":[320,385],"treatment-emergent":[321],"adverse":[322],"events":[323],"(TEAEs)":[324],"occurred":[325,341,371],"62.0%":[327],"all":[329,364],"most":[333,347],"common":[334,348],"(\u226510%)":[335],"being":[336,349],"neutropenia":[337],"(14.0%).":[338],"Serious":[339],"TEAEs":[340,356],"33.0%":[343],"pneumonia":[350],"(4.0%)":[351],"pulmonary":[353],"embolism":[354],"(3.0%).":[355],"led":[357],"death":[359],"2.0%":[361],"unrelated":[365],"treatment.":[368],"Infusion-related":[369],"reactions":[370],"56.0%":[373],"pts;":[375],"majority":[377],"mild":[379],"(4.0%":[380],"grade":[384],"events).":[386],"Conclusions:":[387],"used":[389],"monotherapy":[397],"resulted":[398],"durable,":[400],"deep":[401],"responses":[402],"3-year":[411],"rate":[413],"70%":[415],"irrespective":[418],"status.":[421],"longer":[423],"follow-up,":[424],"no":[425],"new":[426],"concerns":[428],"identified.":[430],"Clinical":[431],"trial":[432],"information:":[433],"NCT02951819.":[434],"[Table:":[435],"see":[436],"text]":[437]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2021-06-22T00:00:00"}